Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*
G. Hartung, W. Queißer(University of Mannheim), Y. Dencausse(Heidelberg University), R. D. Hofheinz(Heidelberg University), Kerstin Jost(Heidelberg University), Walter Lindemann(Heidelberg University), D. Bornbusch(Heidelberg University), Andreas Hochhaus(Jena University Hospital), C. Wojatschek(Heidelberg University), Georg Dietrich(Heidelberg University), James C. Sturm(Princeton University), Annette Kopp‐Schneider(German Cancer Research Center), H. Eschenburg(Heidelberg University), Lutz Edler(German Cancer Research Center), I. Fackler-Schwalbe(Heidelberg University), Michael Gonnermann(Heidelberg University)
Cited by 64
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
Ink-jet printing of doped polymers for organic light emitting devices
|Applied Physics Letters|1998|729
Deterministic hydrodynamics: Taking blood apart
|Proceedings of the National Academy of Sciences|2006|623